Japanese healthtech startup Craif has raised US$22 million in its series C funding to expand its early cancer detection technology into the US and boost research and development.

The funding round was led by existing investor X&KSK, with participation from the Unreasonable Group, Tauns Laboratories, Daiwa House Industry, and Aozora Bank Group.

This round brings Craif’s total funding to US$57 million, valuing the company at just under US$100 million.

Founded in 2018, Craif developed miSignal, a non-invasive urine-based test that detects the risk of seven cancers, and plans to broaden its use.

Craif expects to triple its US$5 million 2024 revenue by 2025, expand miSignal’s capabilities, and is preparing for FDA approval by 2027 while building partnerships across 15 US states.

🔗 Source: TechCrunch

🧠 Food for thought

1️⃣ MicroRNA represents a next frontier in the evolution of cancer biomarkers

Cancer detection methods have evolved dramatically since the introduction of mammography in the 1960s and Pap smears in the 1950s, which helped reduce mortality rates for breast and cervical cancers respectively 1.

While many competitors in the cancer detection space focus on cell-free DNA (cfDNA), Craif’s choice of microRNA as a biomarker represents a scientifically distinct approach with specific advantages for early detection.

The timing of Craif’s Series C coincides with increased scientific recognition of microRNA, which gained heightened visibility after being connected to the 2024 Nobel Prize as mentioned in the original article.

This evolution follows a clear trend in cancer diagnostics history: each new biomarker discovery enables detection at earlier disease stages, with miRNA being actively secreted by early cancer cells rather than simply detected as cellular debris 2.

The use of urine as a collection method further differentiates Craif’s approach, addressing the practical challenges highlighted in multiple studies showing many patients avoid traditional invasive screening methods 3.

2️⃣ The multi-cancer early detection market is entering a high-stakes commercialization phase

The global multi-cancer early detection market is projected to grow substantially from $1.12 billion in 2024 to $2.86 billion by 2030, representing a 17% compound annual growth rate as companies race to capture market share 4.

Craif’s $22 million Series C funding at a valuation under $100 million positions it as a mid-tier player in a field where competitors like GRAIL have attracted significantly larger investments, highlighting the varied capitalization strategies in this sector 5.